Robotics, Ground-breaking Surgery and Medopad Unite
Medopad Patient Monitoring is being used to fight children’s brain cancer.
Diffuse intrinsic pontine glioma (DIPG) is an aggressive form of brainstem tumour predominantly affecting children that cannot be removed.
Professor Steven Gill has developed a cutting-edge procedure involving complex surgery and multiple infusions at regular intervals. This is intended to overcome the blood brain barrier – a natural barrier that protects our brain from toxins and in DIPG’s case, chemotherapy drugs.
Called CED (Convection Enhanced Delivery) and using robotics, surgical tubes are implanted into the brain to deliver drugs directly into the bloodstream for more accurate, effective treatment.
Medopad’s mobile and patient monitoring technology plays an important role both within the hospital and for supporting patients when they are at home between sessions.
- Between infusions, real-time patient monitoring provides doctors with data on patient symptoms – this includes headaches, dizziness, vomiting, visual issues, limb weakness and other difficulties (that most of the time when they occur are temporary)
- Medication reminders ensure patients are taking their necessary supplements at the agreed time
- Personalised questionnaires provide the doctor with data on how the infusion ‘ports’ feel for the patient and their quality of life
- Video recording enables patients to send updates to the doctor wherever they are in the world
Professor Steve Gill, Consultant Neurosurgeon, founder of charity Funding Neuro and inventor of the procedure said: “Convection Enhanced Delivery reveals new information about DIPG with every patient session and it is crucial the children are closely monitored throughout their process. Medopad provides the children with a direct connection to us wherever they are. The solution is also proving crucial in helping us to expand our knowledge of DIPG.”
Dr Stergios Zacharoulis continued: “CED is an incredible blend of medical science and technology, but it is still evolving as a treatment method. The children we look after fly from all over the world for our innovative procedure, so when they return home they need to be monitored. Medopad lets us watch over their progress and provides another vital link between the child and their care team.”
Read about our latest news and achievements.
Medopad’s patient monitoring solution has won Accenture’s HealthTech Innovation Challenge Semi-final in London.
Medopad’s patient monitoring solution has won Accenture’s HealthTech Innovation Challenge Semi-final in London.Read More
Medopad, the UK-based health-tech AI company, today announced over £100m of commercial projects and partnerships in China. This announcement comes as UK Prime Minister Theresa May meets with China’s President Xi following trade talks with Premier Li in Beijing.Read More
and many more...